FindTrial
Sign In

Once daily versus twice daily oral iron supplementation for iron deficiency in chronic kidney disease

Is once daily oral iron supplementation as good as twice daily oral iron supplementation for correction of iron deficiency in subjects with stage G3-4 chronic kidney disease? - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/02/007799
Enrollment
68
Registered
2017-02-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Iron deficient subjects with stage G3-4 chronic kidney disease

Interventions

Intervention1: Ferrous ascorbate 100 mg OD: This group will receive ferrous ascorbate (equivalent to 100 mg elemental iron per tablet) in OD dosage Control Intervention1: Ferrous ascorbate 100 mg BD:

Sponsors

Dr Vivek Kumar
Lead Sponsor
Prof KLGupta
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. Iron deficiency defined as TSAT 2. Clinically stable course for last 3 months

Exclusion criteria

Exclusion criteria: 1. Blood haemoglobin 2. Current use or use within last 3 months of oral or intravenous iron preparations 3. Known/ suspected diagnosis of autoimmune disease 4. Past or present diagnosis of malignancy 5. Known diagnosis of chronic liver disease 6. History of any bleeding diathesis 7. History of gastro-intestinal surgery 8. Present or past diagnosis of peptic ulcer disease, gastro-intestinal bleeding or any form of gastro-intestinal disease predisposing to malabsorption 9. Currently taking gastric acid inhibitors (H2 receptor blockers, proton pump inhibitors) 10. History of allergic reactions to any form of oral or intravenous iron preparations 11. History of prior non-compliance with oral iron therapy on account of gastro-intestinal side effects 12. Current use or use within last 6 months of immunosuppressive drug therapy 13. Pregnancy or lactation, in case of females 14. Life expectancy

Design outcomes

Primary

MeasureTime frame
Change in % transferrin saturation with once daily versus twice daily oral iron supplementation in subjects with stage G3-4 CKD and iron deficiency. Timepoint: 12 weeks—

Secondary

MeasureTime frame
- Change in serum ferritin at 12 weeks with once daily versus twice daily oral iron supplementation in subjects with stage G3-4 CKD and iron deficiency. - Change in blood haemoglobin levels at 12 weeks with once daily versus twice daily oral iron supplementation in subjects with stage G3-4 CKD and iron deficiency. - Change in serum hepcidin levels at 12 weeks with once daily versus twice daily oral iron supplementation in subjects with stage G3-4 CKD and iron deficiency. Timepoint: 12 weeks—

Countries

India

Contacts

Public ContactDr Vivek Sood

PGIMER

enigma165@gmail.com7087429731

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026